Membrane proteins are targeted by over 50 % of marketed pharmaceuticals, and as most membrane proteins are not naturally abundant, they must be produced recombinantly for the structural biology that is a pre-requisite to structure-based drug design. Unfortunately, obtaining high yields of functional, recombinant membrane proteins remains a major bottleneck in contemporary bioscience. Trial-and-error optimisation studies have not (and cannot) reveal mechanistic details of the biology of recombinant protein production, highlighting the need for defined and rational optimisation strategies based upon experimental observation. To this end, we have published a transcriptome and subsequent genetic analysis that has identified genes implicated in high-yielding yeast cell factories. These results have highlighted a role for alterations to a cell's protein synthetic capacity in the production of high yielding cells: paradoxically, reduced protein synthesis favors higher yields of recombinant membrane protein. These results highlight a potential bottleneck at the protein folding or translocation stage of protein production.